Skip to main content
Premium Trial:

Request an Annual Quote

Ardais, Pioneer Hi-Bred, NanoInk


Ardais Takes in $14M Series C

Ardais of Lexington, Mass., closed a $14 million Series C round of venture capital financing in December. The five-year-old firm, which serves as a repository for human tissue for research, took its last round of financing in March 2001 and was valued at $72 million then. Investors in the current round include CIT Group, Pequot Capital, Advanced Technology Ventures, Advent International, Bessemer Venture Partners, and The Kaufmann Fund.


Pioneer Hi-Bred Links With Agilent

Researchers at Pioneer Hi-Bred International Inc., a subsidiary of DuPont headquartered in Des Moines, Iowa, will use Agilent microarrays and Rosetta Resolver informatics systems in their plant genomics research, Agilent announced this week. Pioneer Hi-Bred will examine gene expression during specific stages of a plant’s life.


NanoInk collects $6 Million Investment

NanoInk of Chicago, a Northwestern University spinoff developing a nanolithography technology marketed as the direct-write dip-pen writer, has closed on a $6 million second round of financing led by Lurie Investment Fund. The company said the funding will accelerate the first-quarter release of the product.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.